Seattle based Lumen Bioscience is using the cyanobacteria spirulina to manufacture medicines, which might increase the yield and lower the cost of biologics. Its pipeline includes an obesity program

CEO Brian Finrow describes the characteristics of spirulina that Lumen believes will make it the next new paradigm in developing and manufacturing protein-based medicines. He then walks us through the company’s development plans.